Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	transmembrane receptor protein kinase activity	MET ERBB2 ERBB3 LTBP1	3.03e-05	85	42	4	GO:0019199
GeneOntologyMolecularFunction	microfibril binding	LTBP1 LTBP2	6.44e-05	6	42	2	GO:0050436
GeneOntologyMolecularFunction	ErbB-3 class receptor binding	ERBB2 ERBB3	6.44e-05	6	42	2	GO:0043125
GeneOntologyMolecularFunction	G protein-coupled glutamate receptor activity	GRM2 GRM4	1.54e-04	9	42	2	GO:0098988
GeneOntologyMolecularFunction	adenylate cyclase inhibiting G protein-coupled glutamate receptor activity	GRM2 GRM4	1.54e-04	9	42	2	GO:0001640
GeneOntologyMolecularFunction	E-box binding	MYF6 OLIG3 MYOG	2.86e-04	61	42	3	GO:0070888
GeneOntologyMolecularFunction	growth factor binding	ERBB2 ERBB3 LTBP1 LTBP2	3.18e-04	156	42	4	GO:0019838
GeneOntologyMolecularFunction	transmembrane receptor protein tyrosine kinase activity	MET ERBB2 ERBB3	3.45e-04	65	42	3	GO:0004714
GeneOntologyMolecularFunction	glutamate receptor activity	GRM2 GRM4	1.47e-03	27	42	2	GO:0008066
GeneOntologyBiologicalProcess	positive regulation of muscle tissue development	MYF6 ERBB3 MYOG	2.57e-05	29	41	3	GO:1901863
GeneOntologyCellularComponent	ERBB3:ERBB2 complex	ERBB2 ERBB3	4.13e-06	2	43	2	GO:0038143
MousePheno	abnormal cell differentiation	ILDR2 MET ERBB2 OLIG3 ERBB3 CSF3R MEGF8 ITGB5 MYOG JAG1	6.86e-06	795	32	10	MP:0005076
MousePheno	abnormal Schwann cell precursor morphology	ERBB2 ERBB3	1.52e-05	3	32	2	MP:0004074
MousePheno	decreased Schwann cell precursor number	ERBB2 ERBB3	1.52e-05	3	32	2	MP:0004075
MousePheno	abnormal axon fasciculation	ERBB2 ERBB3 MEGF8	1.87e-05	23	32	3	MP:0009450
MousePheno	abnormal oxygen level	ERBB2 OLIG3 ERBB3 MUC5B LTBP1 MYOG	2.16e-05	256	32	6	MP:0001574
MousePheno	abnormal ophthalmic nerve morphology	ERBB3 MEGF8	3.04e-05	4	32	2	MP:0009798
MousePheno	abnormal neuron differentiation	MET ERBB2 OLIG3 ERBB3 MEGF8 JAG1	3.23e-05	275	32	6	MP:0009937
MousePheno	respiratory failure	MET ERBB2 OLIG3 ERBB3 MYOG	3.36e-05	165	32	5	MP:0001953
MousePheno	decreased respiration	MET ERBB2 OLIG3 ERBB3 MYOG	3.87e-05	170	32	5	MP:0014274
MousePheno	cyanosis	ERBB2 OLIG3 ERBB3 LTBP1 MYOG	1.49e-04	226	32	5	MP:0001575
MousePheno	perinatal lethality, complete penetrance	MET MYF6 ERBB2 OLIG3 ERBB3 LTBP1 ZNRF3 MYOG	1.54e-04	712	32	8	MP:0011089
MousePheno	abnormal myogenesis	MET MYF6 MYOG	2.23e-04	52	32	3	MP:0000729
MousePheno	abnormal trigeminal nerve morphology	ERBB2 ERBB3 MEGF8	2.23e-04	52	32	3	MP:0001065
MousePheno	abnormal respiration	MET MYF6 ERBB2 OLIG3 ERBB3 MUC5B MYOG	3.35e-04	598	32	7	MP:0001943
MousePheno	abnormal petrosal ganglion morphology	ERBB2 ERBB3	4.54e-04	14	32	2	MP:0001084
MousePheno	muscle hypoplasia	MET MYOG	5.23e-04	15	32	2	MP:0000734
Domain	Growth_fac_rcpt_	ATRN ERBB2 ERBB3 BRINP3 LTBP1 LTBP2 MEGF8 SCARF2 JAG1	3.44e-11	156	40	9	IPR009030
Domain	EGF	ATRN BRINP3 LTBP1 LTBP2 MEGF8 SCARF2 ITGB5 JAG1	3.03e-08	235	40	8	SM00181
Domain	EGF_1	ATRN LTBP1 LTBP2 MEGF8 SSPOP SCARF2 ITGB5 JAG1	5.70e-08	255	40	8	PS00022
Domain	EGF_2	ATRN LTBP1 LTBP2 MEGF8 SSPOP SCARF2 ITGB5 JAG1	7.67e-08	265	40	8	PS01186
Domain	EGF_extracell	ATRN LTBP2 SCARF2 ITGB5 JAG1	1.74e-07	60	40	5	IPR013111
Domain	EGF_2	ATRN LTBP2 SCARF2 ITGB5 JAG1	1.74e-07	60	40	5	PF07974
Domain	EGF_3	ATRN LTBP1 LTBP2 MEGF8 SSPOP SCARF2 JAG1	5.98e-07	235	40	7	PS50026
Domain	EGF-like_CS	ATRN LTBP1 LTBP2 MEGF8 SCARF2 ITGB5 JAG1	1.21e-06	261	40	7	IPR013032
Domain	PSI	ATRN MET MEGF8 ITGB5	2.30e-06	44	40	4	IPR016201
Domain	PSI	ATRN MET MEGF8 ITGB5	2.76e-06	46	40	4	SM00423
Domain	Znf-4CXXC_R1	CDCA7 CDCA7L	4.47e-06	2	40	2	IPR018866
Domain	zf-4CXXC_R1	CDCA7 CDCA7L	4.47e-06	2	40	2	PF10497
Domain	EGF	ATRN LTBP1 LTBP2 ITGB5 JAG1	7.03e-06	126	40	5	PF00008
Domain	VWC_out	MUC5B SSPOP JAG1	8.61e-06	19	40	3	SM00215
Domain	EGF-like_dom	ATRN LTBP1 LTBP2 MEGF8 SCARF2 JAG1	1.39e-05	249	40	6	IPR000742
Domain	Basic	MYF6 MYOG	2.68e-05	4	40	2	IPR002546
Domain	Tyr_kinase_EGF/ERB/XmrK_rcpt	ERBB2 ERBB3	2.68e-05	4	40	2	IPR016245
Domain	BASIC	MYF6 MYOG	2.68e-05	4	40	2	SM00520
Domain	Basic	MYF6 MYOG	2.68e-05	4	40	2	PF01586
Domain	EGF_CA	LTBP1 LTBP2 MEGF8 JAG1	3.37e-05	86	40	4	PF07645
Domain	Plexin_repeat	ATRN MET MEGF8	4.32e-05	32	40	3	IPR002165
Domain	PSI	ATRN MET MEGF8	4.32e-05	32	40	3	PF01437
Domain	EGF_Ca-bd_CS	LTBP1 LTBP2 MEGF8 JAG1	5.41e-05	97	40	4	IPR018097
Domain	Laminin_EGF	ATRN MEGF8 SCARF2	5.68e-05	35	40	3	PF00053
Domain	EGF_Lam	ATRN MEGF8 SCARF2	5.68e-05	35	40	3	SM00180
Domain	EGF_CA	LTBP1 LTBP2 MEGF8 JAG1	5.86e-05	99	40	4	PS01187
Domain	ASX_HYDROXYL	LTBP1 LTBP2 MEGF8 JAG1	6.10e-05	100	40	4	PS00010
Domain	GF_recep_IV	ERBB2 ERBB3	6.67e-05	6	40	2	PF14843
Domain	GF_recep_IV	ERBB2 ERBB3	6.67e-05	6	40	2	IPR032778
Domain	VWC	MUC5B SSPOP JAG1	7.29e-05	38	40	3	SM00214
Domain	Laminin_EGF	ATRN MEGF8 SCARF2	7.29e-05	38	40	3	IPR002049
Domain	EGF-type_Asp/Asn_hydroxyl_site	LTBP1 LTBP2 MEGF8 JAG1	7.65e-05	106	40	4	IPR000152
Domain	Furin-like	ERBB2 ERBB3	9.33e-05	7	40	2	PF00757
Domain	Rcpt_L-dom	ERBB2 ERBB3	9.33e-05	7	40	2	IPR000494
Domain	Furin-like_Cys-rich_dom	ERBB2 ERBB3	9.33e-05	7	40	2	IPR006211
Domain	Recep_L_domain	ERBB2 ERBB3	9.33e-05	7	40	2	PF01030
Domain	-	ERBB2 ERBB3	9.33e-05	7	40	2	3.80.20.20
Domain	TB	LTBP1 LTBP2	9.33e-05	7	40	2	PF00683
Domain	VWF_dom	MUC5B SSPOP JAG1	9.86e-05	42	40	3	IPR001007
Domain	-	LTBP1 LTBP2	1.24e-04	8	40	2	3.90.290.10
Domain	GPCR_3_mtglu_rcpt	GRM2 GRM4	1.24e-04	8	40	2	IPR000162
Domain	EGF_CA	LTBP1 LTBP2 MEGF8 JAG1	1.32e-04	122	40	4	SM00179
Domain	EGF-like_Ca-bd_dom	LTBP1 LTBP2 MEGF8 JAG1	1.41e-04	124	40	4	IPR001881
Domain	TB	LTBP1 LTBP2	1.59e-04	9	40	2	PS51364
Domain	TB_dom	LTBP1 LTBP2	1.59e-04	9	40	2	IPR017878
Domain	PSI_integrin	MEGF8 ITGB5	1.59e-04	9	40	2	PF17205
Domain	Integin_beta_N	MEGF8 ITGB5	1.59e-04	9	40	2	IPR033760
Domain	TIL	MUC5B SSPOP	2.91e-04	12	40	2	PF01826
Domain	C8	MUC5B SSPOP	2.91e-04	12	40	2	PF08742
Domain	Unchr_dom_Cys-rich	MUC5B SSPOP	3.44e-04	13	40	2	IPR014853
Domain	NCD3G	GRM2 GRM4	3.44e-04	13	40	2	PF07562
Domain	C8	MUC5B SSPOP	3.44e-04	13	40	2	SM00832
Domain	GPCR_3_9-Cys_dom	GRM2 GRM4	3.44e-04	13	40	2	IPR011500
Domain	GPCR_3_CS	GRM2 GRM4	4.00e-04	14	40	2	IPR017979
Domain	TIL_dom	MUC5B SSPOP	4.00e-04	14	40	2	IPR002919
Domain	VWFD	MUC5B SSPOP	5.27e-04	16	40	2	PS51233
Domain	VWD	MUC5B SSPOP	5.27e-04	16	40	2	SM00216
Domain	VWF_type-D	MUC5B SSPOP	5.27e-04	16	40	2	IPR001846
Domain	VWD	MUC5B SSPOP	5.27e-04	16	40	2	PF00094
Domain	Furin_repeat	ERBB2 ERBB3	6.70e-04	18	40	2	IPR006212
Domain	CTCK_1	MUC5B SSPOP	6.70e-04	18	40	2	PS01185
Domain	FU	ERBB2 ERBB3	6.70e-04	18	40	2	SM00261
Domain	TyrKc	MET ERBB2 ERBB3	8.80e-04	88	40	3	SM00219
Domain	Tyr_kinase_cat_dom	MET ERBB2 ERBB3	8.80e-04	88	40	3	IPR020635
Domain	GPCR_3	GRM2 GRM4	9.15e-04	21	40	2	IPR000337
Domain	G_PROTEIN_RECEP_F3_4	GRM2 GRM4	1.01e-03	22	40	2	PS50259
Domain	7tm_3	GRM2 GRM4	1.01e-03	22	40	2	PF00003
Domain	GPCR_3_C	GRM2 GRM4	1.01e-03	22	40	2	IPR017978
Domain	G_PROTEIN_RECEP_F3_2	GRM2 GRM4	1.01e-03	22	40	2	PS00980
Domain	G_PROTEIN_RECEP_F3_3	GRM2 GRM4	1.01e-03	22	40	2	PS00981
Domain	G_PROTEIN_RECEP_F3_1	GRM2 GRM4	1.01e-03	22	40	2	PS00979
Domain	PROTEIN_KINASE_TYR	MET ERBB2 ERBB3	1.17e-03	97	40	3	PS00109
Domain	Tyr_kinase_AS	MET ERBB2 ERBB3	1.17e-03	97	40	3	IPR008266
Domain	Cys_knot_C	MUC5B SSPOP	1.30e-03	25	40	2	IPR006207
Domain	CTCK_2	MUC5B SSPOP	1.30e-03	25	40	2	PS01225
Domain	-	MYF6 OLIG3 MYOG	1.63e-03	109	40	3	4.10.280.10
Domain	HLH	MYF6 OLIG3 MYOG	1.72e-03	111	40	3	PF00010
Domain	EGF_LAM_2	ATRN MEGF8	1.87e-03	30	40	2	PS50027
Domain	EGF_LAM_1	ATRN MEGF8	1.87e-03	30	40	2	PS01248
Domain	HLH	MYF6 OLIG3 MYOG	1.95e-03	116	40	3	SM00353
Domain	BHLH	MYF6 OLIG3 MYOG	2.00e-03	117	40	3	PS50888
Domain	bHLH_dom	MYF6 OLIG3 MYOG	2.05e-03	118	40	3	IPR011598
Pathway	KEGG_MEDICUS_REFERENCE_REGULATION_OF_GF_RTK_RAS_ERK_SIGNALING_UBIQUITINATION_OF_RTK_BY_CBL	MET ERBB2 ERBB3	2.14e-05	25	31	3	M47934
Pathway	REACTOME_SIGNALING_BY_TGFB_FAMILY_MEMBERS	MYF6 LTBP1 LTBP2 ITGB5 MYOG	2.44e-05	161	31	5	M27871
Pathway	REACTOME_GRB7_EVENTS_IN_ERBB2_SIGNALING	ERBB2 ERBB3	4.66e-05	5	31	2	M26937
Pathway	REACTOME_MOLECULES_ASSOCIATED_WITH_ELASTIC_FIBRES	LTBP1 LTBP2 ITGB5	7.11e-05	37	31	3	M27134
Pathway	REACTOME_ELASTIC_FIBRE_FORMATION	LTBP1 LTBP2 ITGB5	1.20e-04	44	31	3	M26969
Pathway	PID_A6B1_A6B4_INTEGRIN_PATHWAY	MET ERBB2 ERBB3	1.37e-04	46	31	3	M239
Pathway	REACTOME_TGF_BETA_RECEPTOR_SIGNALING_ACTIVATES_SMADS	LTBP1 LTBP2 ITGB5	1.46e-04	47	31	3	M646
Pathway	KEGG_MEDICUS_REFERENCE_RTK_PLCG_ITPR_SIGNALING_PATHWAY	MET ERBB2 ERBB3	2.34e-04	55	31	3	M47952
Pathway	REACTOME_ERBB2_ACTIVATES_PTK6_SIGNALING	ERBB2 ERBB3	2.54e-04	11	31	2	MM15478
Pathway	REACTOME_DOWNREGULATION_OF_ERBB2_ERBB3_SIGNALING	ERBB2 ERBB3	3.05e-04	12	31	2	MM14550
Pathway	REACTOME_DOWNREGULATION_OF_ERBB2_ERBB3_SIGNALING	ERBB2 ERBB3	3.60e-04	13	31	2	M549
Pathway	REACTOME_ERBB2_ACTIVATES_PTK6_SIGNALING	ERBB2 ERBB3	3.60e-04	13	31	2	M27729
Pathway	REACTOME_ERBB2_REGULATES_CELL_MOTILITY	ERBB2 ERBB3	3.60e-04	13	31	2	MM15320
Pathway	WP_HYPOXIADEPENDENT_DIFFERENTIATION_OF_MYOBLASTS	MYF6 MYOG	3.60e-04	13	31	2	MM15894
Pathway	REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING	ERBB2 ERBB3	4.19e-04	14	31	2	MM14761
Pathway	REACTOME_SHC1_EVENTS_IN_ERBB2_SIGNALING	ERBB2 ERBB3	4.19e-04	14	31	2	MM14531
Pathway	PID_ERBB_NETWORK_PATHWAY	ERBB2 ERBB3	4.83e-04	15	31	2	M201
Pathway	REACTOME_ERBB2_REGULATES_CELL_MOTILITY	ERBB2 ERBB3	4.83e-04	15	31	2	M27608
Pathway	WP_GPCRS_CLASS_C_METABOTROPIC_GLUTAMATE_PHEROMONE	GRM2 GRM4	4.83e-04	15	31	2	M39442
Pathway	REACTOME_SEMA4D_IN_SEMAPHORIN_SIGNALING	MET ERBB2	4.83e-04	15	31	2	MM15037
Pathway	WP_GPCRS_CLASS_C_METABOTROPIC_GLUTAMATE_PHEROMONE	GRM2 GRM4	4.83e-04	15	31	2	MM15845
Pathway	REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING	ERBB2 ERBB3	5.51e-04	16	31	2	M570
Pathway	KEGG_MEDICUS_VARIANT_NOTCH_OVEREXPRESSION_TO_NOTCH_SIGNALING_PATHWAY	ERBB2 JAG1	5.51e-04	16	31	2	M47424
Pathway	WP_GLIOBLASTOMA_SIGNALING	MET ERBB2 ERBB3	7.85e-04	83	31	3	M39637
Pathway	REACTOME_CONSTITUTIVE_SIGNALING_BY_ABERRANT_PI3K_IN_CANCER	MET ERBB2 ERBB3	7.85e-04	83	31	3	M27163
Pathway	KEGG_MEDICUS_REFERENCE_GF_RTK_PI3K_SIGNALING_PATHWAY	MET ERBB2 ERBB3	7.85e-04	83	31	3	M47961
Pathway	WP_EGFR_TYROSINE_KINASE_INHIBITOR_RESISTANCE	MET ERBB2 ERBB3	8.13e-04	84	31	3	M39839
Pathway	KEGG_MEDICUS_REFERENCE_GF_RTK_RAS_PI3K_SIGNALING_PATHWAY	MET ERBB2 ERBB3	9.62e-04	89	31	3	M47963
Pathway	REACTOME_SHC1_EVENTS_IN_ERBB2_SIGNALING	ERBB2 ERBB3	1.05e-03	22	31	2	M26929
Pathway	KEGG_MEDICUS_REFERENCE_GF_RTK_RAS_ERK_SIGNALING_PATHWAY	MET ERBB2 ERBB3	1.06e-03	92	31	3	M47927
Pathway	REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COMPLEX	LTBP1 LTBP2 ITGB5	1.13e-03	94	31	3	M1041
Pathway	BIOCARTA_HER2_PATHWAY	ERBB2 ERBB3	1.15e-03	23	31	2	MM1480
Pathway	BIOCARTA_HER2_PATHWAY	ERBB2 ERBB3	1.15e-03	23	31	2	M18719
Pathway	REACTOME_SEMA4D_IN_SEMAPHORIN_SIGNALING	MET ERBB2	1.25e-03	24	31	2	M2243
Pathway	REACTOME_MYOGENESIS	MYF6 MYOG	1.25e-03	24	31	2	MM15174
Pathway	WP_HYPOTHESIZED_PATHWAYS_IN_PATHOGENESIS_OF_CARDIOVASCULAR_DISEASE	LTBP1 LTBP2	1.36e-03	25	31	2	M39713
Pathway	REACTOME_SIGNALING_BY_ERBB2_IN_CANCER	ERBB2 ERBB3	1.47e-03	26	31	2	M29535
Pathway	REACTOME_DOWNREGULATION_OF_ERBB2_SIGNALING	ERBB2 ERBB3	1.47e-03	26	31	2	MM15501
Pathway	REACTOME_TGFBR3_EXPRESSION	MYF6 MYOG	1.71e-03	28	31	2	M48253
Pathway	REACTOME_PI3K_AKT_SIGNALING_IN_CANCER	MET ERBB2 ERBB3	1.77e-03	110	31	3	M27162
Pathway	REACTOME_DOWNREGULATION_OF_ERBB2_SIGNALING	ERBB2 ERBB3	1.83e-03	29	31	2	M27756
Pathway	WP_EXTRACELLULAR_VESICLEMEDIATED_SIGNALING_IN_RECIPIENT_CELLS	MET ERBB2	1.83e-03	29	31	2	M39516
Pathway	REACTOME_MYOGENESIS	MYF6 MYOG	1.83e-03	29	31	2	M853
Pathway	REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK	MET ERBB2 ERBB3	1.91e-03	113	31	3	MM14783
Pathway	REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK	MET ERBB2 ERBB3	2.17e-03	118	31	3	M713
Pathway	REACTOME_MOLECULES_ASSOCIATED_WITH_ELASTIC_FIBRES	LTBP1 LTBP2	2.23e-03	32	31	2	MM14854
Pathway	WP_MAMMARY_GLAND_DEVELOPMENT_PREGNANCY_AND_LACTATION_STAGE_3_OF_4	ERBB2 ERBB3	2.37e-03	33	31	2	M39455
Pathway	REACTOME_CLASS_C_3_METABOTROPIC_GLUTAMATE_PHEROMONE_RECEPTORS	GRM2 GRM4	2.97e-03	37	31	2	MM15067
Pathway	REACTOME_TGF_BETA_RECEPTOR_SIGNALING_ACTIVATES_SMADS	LTBP1 LTBP2	3.13e-03	38	31	2	MM14874
Pathway	REACTOME_CLASS_C_3_METABOTROPIC_GLUTAMATE_PHEROMONE_RECEPTORS	GRM2 GRM4	3.30e-03	39	31	2	M793
Pathway	REACTOME_ELASTIC_FIBRE_FORMATION	LTBP1 LTBP2	3.30e-03	39	31	2	MM14601
Pathway	PID_ERBB2_ERBB3_PATHWAY	ERBB2 ERBB3	4.18e-03	44	31	2	M175
Pathway	REACTOME_SIGNALING_BY_ERBB2	ERBB2 ERBB3	4.18e-03	44	31	2	MM14520
Pathway	WP_ERBB_SIGNALING_PATHWAY	ERBB2 ERBB3	4.56e-03	46	31	2	MM15950
Pathway	REACTOME_SIGNALING_BY_PTK6	ERBB2 ERBB3	4.96e-03	48	31	2	MM15479
Pathway	REACTOME_SIGNALING_BY_TGFBR3	MYF6 MYOG	5.16e-03	49	31	2	M48250
Pathway	REACTOME_SIGNALING_BY_ERBB2	ERBB2 ERBB3	5.37e-03	50	31	2	M553
Pathway	WP_ID_SIGNALING_PATHWAY	MYF6 MYOG	5.37e-03	50	31	2	MM15817
Pathway	REACTOME_SEMAPHORIN_INTERACTIONS	MET ERBB2	5.58e-03	51	31	2	MM14967
Pathway	WP_APOPTOSISRELATED_NETWORK_DUE_TO_ALTERED_NOTCH3_IN_OVARIAN_CANCER	ERBB3 TNFRSF21	6.01e-03	53	31	2	M39688
Pathway	PID_TAP63_PATHWAY	SSPOP JAG1	6.24e-03	54	31	2	M256
Pathway	REACTOME_SIGNALING_BY_PTK6	ERBB2 ERBB3	6.24e-03	54	31	2	M29742
Pubmed	G-CSF influences mouse skeletal muscle development and regeneration by stimulating myoblast proliferation.	MET MYF6 CSF3R MYOG	4.23e-10	10	43	4	21422169
Pubmed	Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer.	MET ERBB2 ERBB3	1.76e-09	3	43	3	25400108
Pubmed	Persistent expression of MNF identifies myogenic stem cells in postnatal muscles.	MET MYF6 MYOG	9.82e-08	8	43	3	9268575
Pubmed	Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells.	MET ERBB2 ERBB3	1.47e-07	9	43	3	23866081
Pubmed	High-density association study of 383 candidate genes for volumetric BMD at the femoral neck and lumbar spine among older men.	MYF6 LTBP1 LTBP2 CSF3R P2RX7 MYOG JAG1	4.26e-07	383	43	7	19453261
Pubmed	Six1 and Six4 homeoproteins are required for Pax3 and Mrf expression during myogenesis in the mouse embryo.	MET MYF6 MYOG	1.18e-06	17	43	3	15788460
Pubmed	H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.	ERBB2 ERBB3	1.49e-06	2	43	2	20581867
Pubmed	Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers.	ERBB2 ERBB3	1.49e-06	2	43	2	35108525
Pubmed	Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.	ERBB2 ERBB3	1.49e-06	2	43	2	17203234
Pubmed	Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling.	ERBB2 ERBB3	1.49e-06	2	43	2	22733765
Pubmed	Latent transforming growth factor-β binding proteins (LTBP-1 and LTBP-2) and gingiva keratinization.	LTBP1 LTBP2	1.49e-06	2	43	2	25858550
Pubmed	MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.	MET ERBB2	1.49e-06	2	43	2	23825050
Pubmed	Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.	ERBB2 ERBB3	1.49e-06	2	43	2	16199884
Pubmed	Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.	ERBB2 ERBB3	1.49e-06	2	43	2	30068375
Pubmed	HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value.	ERBB2 ERBB3	1.49e-06	2	43	2	25739551
Pubmed	Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.	ERBB2 ERBB3	1.49e-06	2	43	2	38441358
Pubmed	Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer.	ERBB2 ERBB3	1.49e-06	2	43	2	10205169
Pubmed	In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer.	ERBB2 ERBB3	1.49e-06	2	43	2	21638049
Pubmed	MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.	MET ERBB3	1.49e-06	2	43	2	17463250
Pubmed	Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.	ERBB2 ERBB3	1.49e-06	2	43	2	17638894
Pubmed	The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.	ERBB2 ERBB3	1.49e-06	2	43	2	27317872
Pubmed	The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.	ERBB2 ERBB3	1.49e-06	2	43	2	12853564
Pubmed	Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.	ERBB2 ERBB3	1.49e-06	2	43	2	21709195
Pubmed	Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors.	ERBB2 ERBB3	1.49e-06	2	43	2	12134143
Pubmed	HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells.	MET ERBB2	1.49e-06	2	43	2	29223420
Pubmed	Higher-order association states of cellular ERBB3 probed with photo-cross-linkable aptamers.	ERBB2 ERBB3	1.49e-06	2	43	2	18942860
Pubmed	The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers.	ERBB2 ERBB3	1.49e-06	2	43	2	33907275
Pubmed	Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.	ERBB2 ERBB3	1.49e-06	2	43	2	22848366
Pubmed	A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2.	ERBB2 ERBB3	1.49e-06	2	43	2	18056992
Pubmed	HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.	ERBB2 ERBB3	1.49e-06	2	43	2	25915155
Pubmed	MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.	MET ERBB2	1.49e-06	2	43	2	22238368
Pubmed	Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.	ERBB2 ERBB3	1.49e-06	2	43	2	25017122
Pubmed	Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.	ERBB2 ERBB3	1.49e-06	2	43	2	23698633
Pubmed	The significance of ErbB2/3 in the conversion of induced pluripotent stem cells into cancer stem cells.	ERBB2 ERBB3	1.49e-06	2	43	2	35177646
Pubmed	Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.	ERBB2 ERBB3	1.49e-06	2	43	2	7538656
Pubmed	Pharmacological targeting of the pseudokinase Her3.	ERBB2 ERBB3	1.49e-06	2	43	2	25326665
Pubmed	Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patients.	ERBB2 ERBB3	1.49e-06	2	43	2	26208475
Pubmed	Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells.	MET ERBB3	1.49e-06	2	43	2	35249128
Pubmed	Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.	ERBB2 ERBB3	1.49e-06	2	43	2	29959202
Pubmed	HER2 expression as a potential marker for response to therapy targeted to the EGFR.	ERBB2 ERBB3	1.49e-06	2	43	2	16622439
Pubmed	ErbB2 and ErbB3 regulate recovery from dextran sulfate sodium-induced colitis by promoting mouse colon epithelial cell survival.	ERBB2 ERBB3	1.49e-06	2	43	2	22157714
Pubmed	c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma.	MET ERBB2	1.49e-06	2	43	2	11895493
Pubmed	Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations.	ERBB2 ERBB3	1.49e-06	2	43	2	31932682
Pubmed	Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling.	ERBB2 ERBB3	1.49e-06	2	43	2	20589763
Pubmed	Neuregulin induces the rapid association of focal adhesion kinase with the erbB2-erbB3 receptor complex in schwann cells.	ERBB2 ERBB3	1.49e-06	2	43	2	10799311
Pubmed	c-MET positivity and its relationship with histopathological findings in gastric carcinomas exhibiting HER2 gene expression.	MET ERBB2	1.49e-06	2	43	2	36308181
Pubmed	Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines.	ERBB2 ERBB3	1.49e-06	2	43	2	22806884
Pubmed	Oncogenic ERBB3 mutations in human cancers.	ERBB2 ERBB3	1.49e-06	2	43	2	23680147
Pubmed	Structures of Gi-bound metabotropic glutamate receptors mGlu2 and mGlu4.	GRM2 GRM4	1.49e-06	2	43	2	34135510
Pubmed	Correlation analysis of mesenchymal-epithelial transition factor protein and human epidermal growth receptor 2 protein expression in 1479 cases of lung adenocarcinoma in China.	MET ERBB2	1.49e-06	2	43	2	29400000
Pubmed	Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.	ERBB2 ERBB3	1.49e-06	2	43	2	23843458
Pubmed	Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.	ERBB2 ERBB3	1.49e-06	2	43	2	34171264
Pubmed	Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain.	ERBB2 ERBB3	1.49e-06	2	43	2	23688700
Pubmed	HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways.	ERBB2 ERBB3	1.49e-06	2	43	2	22983903
Pubmed	HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.	ERBB2 ERBB3	1.49e-06	2	43	2	27358485
Pubmed	Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS.	GRM2 GRM4	1.49e-06	2	43	2	24381270
Pubmed	Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3.	MET ERBB3	1.49e-06	2	43	2	30421568
Pubmed	PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.	ERBB2 GRN	1.49e-06	2	43	2	16857791
Pubmed	Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.	MET ERBB2	1.49e-06	2	43	2	18316611
Pubmed	Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.	ERBB2 ERBB3	1.49e-06	2	43	2	21385943
Pubmed	CRISPR-assisted receptor deletion reveals distinct roles for ERBB2 and ERBB3 in skin keratinocytes.	ERBB2 ERBB3	1.49e-06	2	43	2	28805349
Pubmed	Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association.	ERBB2 ERBB3	1.49e-06	2	43	2	12000754
Pubmed	Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.	ERBB2 ERBB3	1.49e-06	2	43	2	22248472
Pubmed	[Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma].	MET ERBB2	1.49e-06	2	43	2	18172343
Pubmed	Lung tumorigenesis associated with erb-B-2 and erb-B-3 overexpression in human erb-B-3 transgenic mice is enhanced by methylnitrosourea.	ERBB2 ERBB3	1.49e-06	2	43	2	12483526
Pubmed	Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor alpha (TGF-alpha)- and epidermal growth factor (EGF)-induced human PC-3 prostate cancer cell proliferation.	ERBB2 ERBB3	1.49e-06	2	43	2	12888923
Pubmed	Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.	ERBB2 ERBB3	1.49e-06	2	43	2	25112701
Pubmed	Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.	ERBB2 ERBB3	1.49e-06	2	43	2	14737100
Pubmed	Expression of mutant human epidermal receptor 3 attenuates lung fibrosis and improves survival in mice.	ERBB2 ERBB3	1.49e-06	2	43	2	15731393
Pubmed	Overexpression of ErbB2 and ErbB3 receptors in Schwann cells of patients with Charcot-Marie-tooth disease type 1A.	ERBB2 ERBB3	1.49e-06	2	43	2	16307437
Pubmed	Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.	ERBB2 ERBB3	1.49e-06	2	43	2	16168116
Pubmed	Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.	ERBB2 ERBB3	1.49e-06	2	43	2	26261492
Pubmed	Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy.	ERBB2 ERBB3	1.49e-06	2	43	2	29654069
Pubmed	Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.	ERBB2 ERBB3	1.49e-06	2	43	2	29338072
Pubmed	Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.	ERBB2 ERBB3	1.49e-06	2	43	2	24678002
Pubmed	HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors.	ERBB2 ERBB3	1.49e-06	2	43	2	19622585
Pubmed	Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies.	ERBB2 ERBB3	1.49e-06	2	43	2	26138066
Pubmed	Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients.	ERBB2 ERBB3	1.49e-06	2	43	2	14614020
Pubmed	NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.	ERBB2 ERBB3	4.48e-06	3	43	2	26770651
Pubmed	EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer.	ERBB2 ERBB3	4.48e-06	3	43	2	35902718
Pubmed	[Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].	ERBB2 ERBB3	4.48e-06	3	43	2	20038315
Pubmed	Relation between transforming growth factor-β1 expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers.	ERBB2 LTBP1	4.48e-06	3	43	2	22015652
Pubmed	Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.	ERBB2 ERBB3	4.48e-06	3	43	2	17426253
Pubmed	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma.	ERBB2 ERBB3	4.48e-06	3	43	2	27070783
Pubmed	HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC.	ERBB2 ERBB3	4.48e-06	3	43	2	28656214
Pubmed	Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4).	ERBB2 ERBB3	4.48e-06	3	43	2	28653892
Pubmed	FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.	MET ERBB2	4.48e-06	3	43	2	28343375
Pubmed	Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment.	ERBB2 ERBB3	4.48e-06	3	43	2	24346286
Pubmed	A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.	ERBB2 ERBB3	4.48e-06	3	43	2	18632642
Pubmed	Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.	ERBB2 ERBB3	4.48e-06	3	43	2	25471734
Pubmed	EGFR/ERBB receptors differentially modulate sebaceous lipogenesis.	ERBB2 ERBB3	4.48e-06	3	43	2	25889637
Pubmed	The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors.	ERBB2 ERBB3	4.48e-06	3	43	2	29556616
Pubmed	FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.	MET ERBB2	4.48e-06	3	43	2	24306956
Pubmed	WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling.	ERBB2 ERBB3	4.48e-06	3	43	2	26804171
Pubmed	Treml4, an Ig superfamily member, mediates presentation of several antigens to T cells in vivo, including protective immunity to HER2 protein.	ERBB2 TREML4	4.48e-06	3	43	2	22210914
Pubmed	Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.	MET ERBB2	4.48e-06	3	43	2	27770386
Pubmed	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.	MET ERBB2	4.48e-06	3	43	2	23470965
Pubmed	The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.	ERBB2 ERBB3	4.48e-06	3	43	2	22262199
Pubmed	Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3.	ERBB2 ERBB3	4.48e-06	3	43	2	7592681
Pubmed	Neuregulin-1-mediated ErbB2-ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation.	ERBB2 ERBB3	4.48e-06	3	43	2	26490994
Interaction	LYPD1 interactions	ATRN GBF1 MEGF8 ITGB5	5.22e-06	58	40	4	int:LYPD1
Interaction	SHD interactions	MET ERBB2 ERBB3	5.79e-06	18	40	3	int:SHD
Interaction	SHC4 interactions	MET ERBB2 ERBB3	1.09e-05	22	40	3	int:SHC4
Interaction	SLA2 interactions	MET ERBB2 ERBB3	1.42e-05	24	40	3	int:SLA2
Interaction	SOCS5 interactions	MET ERBB2 ERBB3	1.42e-05	24	40	3	int:SOCS5
Interaction	SH2B3 interactions	MET ERBB2 ERBB3	1.62e-05	25	40	3	int:SH2B3
Interaction	HSH2D interactions	MET ERBB2 ERBB3	1.62e-05	25	40	3	int:HSH2D
Interaction	STAP1 interactions	MET ERBB2 ERBB3	2.05e-05	27	40	3	int:STAP1
Interaction	ATN1 interactions	GRN OLIG3 LTBP1 MEGF8 SSPOP	3.30e-05	187	40	5	int:ATN1
Interaction	SH2D1B interactions	MET ERBB2 ERBB3	3.45e-05	32	40	3	int:SH2D1B
Interaction	SH2B1 interactions	MET ERBB2 ERBB3	3.45e-05	32	40	3	int:SH2B1
Interaction	SOCS3 interactions	MET ERBB2 ERBB3 CSF3R	6.60e-05	110	40	4	int:SOCS3
Interaction	TNS1 interactions	MET ERBB2 ERBB3	7.33e-05	41	40	3	int:TNS1
Interaction	SHC1 interactions	MET ERBB2 GRN ERBB3 GBF1 CSF3R	7.38e-05	362	40	6	int:SHC1
Interaction	SOS1 interactions	PRICKLE2 MET ERBB2 ERBB3	8.39e-05	117	40	4	int:SOS1
Interaction	MATK interactions	MET ERBB2 ERBB3	8.46e-05	43	40	3	int:MATK
Interaction	SHC2 interactions	MET ERBB2 ERBB3	9.07e-05	44	40	3	int:SHC2
Interaction	SH2D1A interactions	MET ERBB2 ERBB3	9.70e-05	45	40	3	int:SH2D1A
Interaction	TMA7 interactions	ERBB2 ERBB3 GVINP1	1.04e-04	46	40	3	int:TMA7
Interaction	SH3BP2 interactions	MET ERBB2 ERBB3	1.18e-04	48	40	3	int:SH3BP2
Interaction	MUC4 interactions	ERBB2 ERBB3	1.37e-04	9	40	2	int:MUC4
Interaction	FBXO2 interactions	ATRN MET GRN MEGF8 ITGB5 JAG1	1.48e-04	411	40	6	int:FBXO2
Interaction	SH2D2A interactions	MET ERBB2 ERBB3	1.50e-04	52	40	3	int:SH2D2A
Interaction	VAV3 interactions	MET ERBB2 ERBB3	1.77e-04	55	40	3	int:VAV3
Interaction	SLURP1 interactions	ATRN MET GRN MEGF8	1.87e-04	144	40	4	int:SLURP1
Interaction	ZNF408 interactions	ATRN GRN LTBP1 LTBP2	1.92e-04	145	40	4	int:ZNF408
Interaction	TXK interactions	MET ERBB2 ERBB3	1.97e-04	57	40	3	int:TXK
Interaction	CDCA7 interactions	CDCA7 CDCA7L	2.09e-04	11	40	2	int:CDCA7
Interaction	FES interactions	MET ERBB2 ERBB3	2.41e-04	61	40	3	int:FES
Interaction	BTNL2 interactions	ATRN MET MEGF8 ITGB5	2.48e-04	155	40	4	int:BTNL2
Interaction	ITK interactions	MET ERBB2 ERBB3	2.53e-04	62	40	3	int:ITK
Interaction	LRIG1 interactions	MET ERBB2 ERBB3	2.65e-04	63	40	3	int:LRIG1
Interaction	BCAR3 interactions	MET ERBB2 ERBB3	3.04e-04	66	40	3	int:BCAR3
Interaction	JAK2 interactions	ERBB2 ERBB3 MUC5B CSF3R	3.15e-04	165	40	4	int:JAK2
Interaction	SMIM20 interactions	ERBB2 ERBB3	3.44e-04	14	40	2	int:SMIM20
Interaction	SHC3 interactions	MET ERBB2 ERBB3	3.93e-04	72	40	3	int:SHC3
Interaction	ASIP interactions	ATRN GRN	4.53e-04	16	40	2	int:ASIP
Interaction	FBXO6 interactions	ATRN MET GRN MUC5B LTBP1 MEGF8 ITGB5	4.69e-04	717	40	7	int:FBXO6
Interaction	LGALS1 interactions	ATRN MET GRN ITGB5 JAG1	4.83e-04	332	40	5	int:LGALS1
Interaction	TMEM134 interactions	ERBB2 ERBB3	5.13e-04	17	40	2	int:TMEM134
Interaction	CALM3 interactions	MET MYF6 ERBB2 ERBB3 MYOG	5.60e-04	343	40	5	int:CALM3
Interaction	HCK interactions	MET ERBB2 ERBB3 CSF3R	5.69e-04	193	40	4	int:HCK
Interaction	SHB interactions	MET ERBB2 ERBB3	6.17e-04	84	40	3	int:SHB
Interaction	NAALADL2 interactions	ERBB2 GRM2	6.43e-04	19	40	2	int:NAALADL2
Interaction	HOXA1 interactions	GRN LTBP1 MEGF8 ZNRF3 RGS19	6.62e-04	356	40	5	int:HOXA1
Interaction	TNS3 interactions	MET ERBB2 ERBB3	6.84e-04	87	40	3	int:TNS3
Interaction	TXN interactions	MET ERBB2 GRN ERBB3 GRM2	6.96e-04	360	40	5	int:TXN
Interaction	TEC interactions	MET ERBB2 ERBB3	7.55e-04	90	40	3	int:TEC
Interaction	PTPN11 interactions	MET ERBB2 ERBB3 GBF1 CSF3R	7.69e-04	368	40	5	int:PTPN11
Interaction	ZAP70 interactions	MET ERBB2 ERBB3	8.05e-04	92	40	3	int:ZAP70
Interaction	FGR interactions	MET ERBB2 ERBB3	8.31e-04	93	40	3	int:FGR
Interaction	HSD17B12 interactions	ILDR2 MET ERBB2 GRM2	9.28e-04	220	40	4	int:HSD17B12
Interaction	ID4 interactions	MYF6 MYOG	9.47e-04	23	40	2	int:ID4
Interaction	SFTPC interactions	ATRN MET MEGF8 SCARF2	9.60e-04	222	40	4	int:SFTPC
Interaction	SEC61A1 interactions	MET ERBB2 GBF1 GRM2	9.76e-04	223	40	4	int:SEC61A1
Interaction	VAV2 interactions	MET ERBB2 ERBB3	9.96e-04	99	40	3	int:VAV2
Interaction	PLCG2 interactions	MET ERBB2 ERBB3	1.03e-03	100	40	3	int:PLCG2
Interaction	DUSP18 interactions	ERBB2 ERBB3	1.03e-03	24	40	2	int:DUSP18
Interaction	CSRP3 interactions	MYF6 MYOG	1.03e-03	24	40	2	int:CSRP3
Interaction	CRKL interactions	ERBB2 GRN ERBB3 GBF1	1.04e-03	227	40	4	int:CRKL
Interaction	VAV1 interactions	PRICKLE2 MET ERBB2 ERBB3	1.06e-03	228	40	4	int:VAV1
Interaction	PIK3R2 interactions	MET ERBB2 GRN ERBB3	1.09e-03	230	40	4	int:PIK3R2
Interaction	RNF133 interactions	GBF1 RNF133	1.12e-03	25	40	2	int:RNF133
Interaction	PTK6 interactions	MET ERBB2 ERBB3	1.15e-03	104	40	3	int:PTK6
Interaction	KDELR2 interactions	MET ERBB2 GBF1	1.15e-03	104	40	3	int:KDELR2
Interaction	TNS2 interactions	MET ERBB2 ERBB3 ITGB5	1.18e-03	235	40	4	int:TNS2
Interaction	CLGN interactions	MET ERBB2 ERBB3 GRM2	1.18e-03	235	40	4	int:CLGN
Interaction	GNA15 interactions	GRM2 GRM4	1.21e-03	26	40	2	int:GNA15
Interaction	DAB1 interactions	ERBB2 ERBB3 ITGB5	1.25e-03	107	40	3	int:DAB1
Interaction	ABL2 interactions	MET ERBB2 ERBB3	1.25e-03	107	40	3	int:ABL2
Interaction	ZNF532 interactions	ERBB2 ERBB3	1.31e-03	27	40	2	int:ZNF532
Interaction	NCK1 interactions	MET ERBB2 ERBB3 SCARF2	1.36e-03	244	40	4	int:NCK1
GeneFamily	Latent transforming growth factor beta binding proteins	LTBP1 LTBP2	1.59e-05	4	30	2	628
GeneFamily	Erb-b2 receptor tyrosine kinases	ERBB2 ERBB3	1.59e-05	4	30	2	1096
GeneFamily	Glutamate metabotropic receptors\|Protein phosphatase 1 regulatory subunits	GRM2 GRM4	7.41e-05	8	30	2	281
GeneFamily	Basic helix-loop-helix proteins	MYF6 OLIG3 MYOG	7.89e-04	110	30	3	420
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	ERBB2 CSF3R TNFRSF21 JAG1	3.89e-03	394	30	4	471
Coexpression	GSE369_PRE_VS_POST_IL6_INJECTION_SOCS3_KO_LIVER_DN	ATRN GRN GBF1 MEGF8 RGS19	1.87e-05	200	43	5	M5977
Coexpression	GSE27670_BLIMP1_VS_LMP1_TRANSDUCED_GC_BCELL_UP	GRN ZNFX1 ERBB3 CSF3R ITGB5	1.87e-05	200	43	5	M8209
Coexpression	HE_LIM_SUN_FETAL_LUNG_C3_OMD_POS_ENDOTHELIAL_CELL	GOLGA8B MET ERBB2 LTBP2 ITGB5 JAG1	2.36e-05	355	43	6	M45758
Coexpression	PEDRIOLI_MIR31_TARGETS_DN	KIAA0040 ARSD CSF3R GVINP1 P2RX7 SCARF2	5.49e-05	413	43	6	M2494
CoexpressionAtlas	Myeloid Cells, Mo.6C+II-.BM, B220neg CD3neg CD115+ Ly-6C+, Bone marrow, avg-3	MET GRN TREML4 CSF3R CDCA7 TNFRSF21 ITGB5	1.24e-05	391	43	7	GSM854329_500
CoexpressionAtlas	Myeloid Cells, MF.Lv, CD45+ F4/80+ CD11b+, Liver, avg-2	MET GRN TREML4 CSF3R TNFRSF21 ITGB5	1.50e-04	402	43	6	GSM854320_500
CoexpressionAtlas	kidney_P4_CapMesRenVes_Crym_top-relative-expression-ranked_1000	MET KIAA0040 LTBP1 ZNRF3 CDCA7 TNFRSF21 CDCA7L JAG1	1.52e-04	783	43	8	gudmap_kidney_P4_CapMesRenVes_Crym_1000
CoexpressionAtlas	B cells, MLP.BM, CD19- IgM- CD43+ CD24intermediate AA4.1+ CD45R- CD, Bone marrow, avg-2	MET CSF3R CDCA7 TNFRSF21 ITGB5 CDCA7L	1.54e-04	404	43	6	GSM791129_500
CoexpressionAtlas	Myeloid Cells, Mo.6C+II+.Bl, CD115+ B220- CD43+ Ly6C+ MHCIIint, Blood, avg-4	MET GRN TREML4 CSF3R TNFRSF21 ITGB5	1.62e-04	408	43	6	GSM605868_500
CoexpressionAtlas	Myeloid Cells, Mo.6C-II-.BM, B220neg CD3neg CD115+ Ly-6C/Glo CD43+, Bone marrow, avg-3	GRN TREML4 CSF3R CDCA7 TNFRSF21 ITGB5	1.64e-04	409	43	6	GSM854332_500
CoexpressionAtlas	Myeloid Cells, Mo.6C+II-.Bl, Cd115+ B220- CD43+ Ly6C+ MHCII-, Blood, avg-3	MET GRN TREML4 CSF3R TNFRSF21 ITGB5	1.69e-04	411	43	6	GSM605872_500
CoexpressionAtlas	Myeloid Cells, Mo.6C-II+.Bl, CD115+ B220- CD43+ Ly6C- MHCIIhi, Blood, avg-2	MET GRN TREML4 CSF3R TNFRSF21 ITGB5	1.73e-04	413	43	6	GSM605878_500
CoexpressionAtlas	B cells, MLP.BM, CD19- IgM- CD43+ CD24- AA4.1+ CD45R- CD117+ IL7R-, Bone marrow, avg-2	MET CSF3R CDCA7 TNFRSF21 ITGB5 CDCA7L	1.95e-04	422	43	6	GSM791124_500
ToppCell	Parenchymal-10x3prime_v2-Epithelial-Epi_airway_secretory-Secretory_Club\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	MET ERBB2 ERBB3 MUC5B GRM4	1.22e-06	195	43	5	b9e8f405f6d837bb39b615836d3e2df349737c0e
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW23-Macroglial-Astrocyte\|GW23 / Sample Type, Dataset, Time_group, and Cell type.	ERBB3 BRINP3 LTBP1 P2RX7 CDCA7L	1.39e-06	200	43	5	4fe3b2d80c567c18621bff3341f9a73578c81621
ToppCell	droplet-Lung-nan-3m-Myeloid-intermediate_monocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MT4 ERBB3 TREML4 TNFRSF21	1.10e-05	143	43	4	4d11d53330a9197275a8851e1bbf55a113715a09
ToppCell	droplet-Lung-nan-3m-Myeloid-Intermediate_Monocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MT4 ERBB3 TREML4 TNFRSF21	1.10e-05	143	43	4	8b9f4d87d5faac7752c83e1992491fc5550600f8
ToppCell	P15-Epithelial-epithelial_progenitor_cell-epithelial_progenitor_cell\|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	MET ERBB3 MUC5B NALF2	1.22e-05	147	43	4	aba44c7057096483c4293a7ebcf8ccc8baed0231
ToppCell	facs-Lung-EPCAM-3m-Myeloid-Nonclassical_Monocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BRINP3 TREML4 CSF3R TNFRSF21	1.62e-05	158	43	4	b0508a600994090c6aafd8d779437190a33ad821
ToppCell	facs-Lung-EPCAM-3m-Myeloid-non-classical_monocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BRINP3 TREML4 CSF3R TNFRSF21	1.62e-05	158	43	4	a816cc095452308d06f87b77467e2a8c6361fd2a
ToppCell	droplet-Spleen-SPLEEN-1m-Hematologic-proerythroblast\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TREML4 CSF3R TNFRSF21 ITGB5	2.07e-05	168	43	4	f3b7a7df54988de77dcc7066e2fc1feb9c280b13
ToppCell	droplet-Spleen-SPLEEN-1m-Hematologic\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TREML4 CSF3R TNFRSF21 ITGB5	2.16e-05	170	43	4	7cb7ad9ab064b6ea452545d145e5b1d4090cd4c1
ToppCell	droplet-Spleen-SPLEEN-1m-Hematologic-nan\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TREML4 CSF3R TNFRSF21 ITGB5	2.16e-05	170	43	4	db7cee7e518debb2cbe9eeae05d47e14b69cb8e3
ToppCell	wk_20-22-Epithelial-Proximal_epithelial-Proximal_secretory_2\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	ERBB3 MUC5B GRM4 NALF2	2.32e-05	173	43	4	d1e47c87bd4750801f3531f66a56c5dccb4ea64c
ToppCell	facs-Limb_Muscle-Muscle_Diaphragm-18m-Myeloid-new-cluster\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ERBB3 TREML4 CSF3R RGS19	2.37e-05	174	43	4	718e14d9a4264456459bec4c062c94c3a848d43a
ToppCell	facs-Limb_Muscle-Muscle_Diaphragm-18m-Myeloid-macrophage\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ERBB3 TREML4 CSF3R RGS19	2.42e-05	175	43	4	61fdafba120fbda063d4dc05263d6f8d1dcab1e1
ToppCell	facs-Limb_Muscle-Muscle_Diaphragm-18m-Myeloid\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ERBB3 TREML4 CSF3R RGS19	2.42e-05	175	43	4	8de8031fdf2af187642833feb80caa64932897cf
ToppCell	5'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-myocytic_fibroblast-Myofibroblasts-Myofibroblasts_L.2.3.2.2\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ILDR2 BRINP3 LTBP1 LTBP2	2.77e-05	181	43	4	b116c68393d8836bac080f81a8fcbeb52e0403e7
ToppCell	droplet-Thymus-nan-18m-Myeloid\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MET ERBB2 GRN MEGF8	2.83e-05	182	43	4	f6717e97e87513384149800c9fd8dea821ab9393
ToppCell	droplet-Thymus-nan-18m-Myeloid-professional_antigen_presenting_cell\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MET ERBB2 GRN MEGF8	2.83e-05	182	43	4	c33b0d532822186a1e8e645500347972468718c0
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_C_(IT_L4_RORB)-Exc_L4_RORB_CCDC168\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ILDR2 MET BRINP3 GRM4	3.01e-05	185	43	4	5a0340c25196453f19e424d346efbf66d2c53ac3
ToppCell	10x5'-bone_marrow-Hematopoietic_Erythro-Mega-Mega-Mast\|bone_marrow / Manually curated celltypes from each tissue	PRICKLE2 LTBP1 WDR90 CDCA7	3.01e-05	185	43	4	a62ebaff92f2ed27b27b32c27c89cfbe2cb35116
ToppCell	droplet-Trachea-3m-Mesenchymal-fibroblast-fibroblast_of_trachea-tracheal_fibroblast_l1\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	LTBP2 SCARF2 ITGB5 JAG1	3.08e-05	186	43	4	4e983de6d2515082f9e555f4f949cec84281c140
ToppCell	tumor_Lymph_Node_/_Brain-Fibroblasts-Undetermined\|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass	PRICKLE2 LTBP1 TNFRSF21 ITGB5	3.21e-05	188	43	4	8231e635706a296db6b6da1029a33bbc1b52478e
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM2_(12)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	BRINP3 LTBP1 LTBP2 JAG1	3.21e-05	188	43	4	3004e961d214919e08c7cd5f10c3de5cf85b35a3
ToppCell	Non-neuronal-Non-dividing-OPC-OPC\|World / Primary Cells by Cluster	ERBB3 BRINP3 P2RX7 CDCA7L	3.27e-05	189	43	4	ddf5be73912570c32c50f4ac2902da9b590526f8
ToppCell	Non-neuronal-Non-dividing-OPC\|World / Primary Cells by Cluster	ERBB3 BRINP3 P2RX7 CDCA7L	3.27e-05	189	43	4	13848a031ab896b4b24c8319e4745b9b17ff9cfd
ToppCell	Non-neuronal-Non-dividing-OPC-OPC-30\|World / Primary Cells by Cluster	ERBB3 BRINP3 P2RX7 CDCA7L	3.27e-05	189	43	4	313d165fad541ec6e8dd524b88856e2c93eeb681
ToppCell	BL-critical-LOC-Epithelial-Secretory\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	MET ERBB2 ERBB3 MUC5B	3.34e-05	190	43	4	f2abe4bc28e934287e2dcd7b9399d5af78c5c8cf
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_C_(IT_L4_RORB)\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ILDR2 MET BRINP3 GRM4	3.34e-05	190	43	4	1bbbf0ce222e51f9fd2daca0c18d3965fd4efd31
ToppCell	5'-GW_trimst-2-LargeIntestine-Epithelial-epithelial_progenitor_cell-Stem_cells\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ERBB3 BRINP3 ZNRF3 CDCA7	3.41e-05	191	43	4	a8d77095ba20b47fc70ba04f80759fbce873253d
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM1_(8)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	ZNRF3 CDCA7 ITGB5 JAG1	3.48e-05	192	43	4	c4efc170852abbcf0c53c2b0f8a0cc9fe7f116c8
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_C_(IT_L4_RORB)-Exc_L4_RORB_BHLHE22\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ILDR2 MET BRINP3 GRM4	3.48e-05	192	43	4	25460ca9ebd3d49f666394cf99ab77a5e8f77250
ToppCell	COVID-19-Fibroblasts-Other_FB\|COVID-19 / group, cell type (main and fine annotations)	PRICKLE2 BRINP3 LTBP1 LTBP2	3.55e-05	193	43	4	e6b75be08e33c1de079fb5c02f0b4468128b369c
ToppCell	Club_cells\|World / lung cells shred on cell class, cell subclass, sample id	MET ERBB2 ERBB3 MUC5B	3.55e-05	193	43	4	9d3165dc5763a07a7d873f497624d9d6528fa2db
ToppCell	3'-Child09-12-SmallIntestine-Hematopoietic-Myeloid-LYVE1+_Macrophage\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	GRN CSF3R TNFRSF21 ITGB5	3.63e-05	194	43	4	8e2819a9d0529f7b2de1a7c1190575175d6173ee
ToppCell	control-Myeloid-Neutrophils_2\|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	KIAA0040 ZNFX1 TREML4 CSF3R	3.63e-05	194	43	4	267e213e8efe53aadfe553a2ca010a0e3b4b8939
ToppCell	Monocytes-M2-like_CD16+_macrophages\|World / Immune cells in Kidney/Urine in Lupus Nephritis	GRN LTBP2 CSF3R ITGB5	3.70e-05	195	43	4	10fa47bdcf6c9784ea930b75a5861e139421feed
ToppCell	NS-critical-LOC-Epithelial-Secretory\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	MET ERBB2 ERBB3 MUC5B	3.70e-05	195	43	4	b0d782eeee30c797b4da9b3be29b864983fd9e71
ToppCell	NS-critical-d_16-33-Epithelial-Secretory\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	MET ERBB2 ERBB3 MUC5B	3.85e-05	197	43	4	a72047b7428c0d4aaf016c1ac23dc30919260fd8
ToppCell	tumor_Lung-Fibroblasts-Myofibroblasts\|tumor_Lung / Location, Cell class and cell subclass	LTBP1 LTBP2 SCARF2 ITGB5	3.93e-05	198	43	4	31f9181dab689aabe9c6182c2ef7de65ba3f0ff6
ToppCell	Biopsy_Control_(H.)-Epithelial-SCGB3A2+_SCGB1A1+\|Biopsy_Control_(H.) / Sample group, Lineage and Cell type	MET ERBB2 ERBB3 MUC5B	3.93e-05	198	43	4	a3d4b6e4259ded2193d94d2ff6d48cf67214fc35
ToppCell	Non-neuronal-Dividing-IPC-IPC-new\|World / Primary Cells by Cluster	LTBP1 CDCA7 CDCA7L JAG1	3.93e-05	198	43	4	11d2d4d179bc31ef2897d7ceeaf9bed1b20cbdc0
ToppCell	Non-neuronal-Dividing-IPC-IPC-new-9\|World / Primary Cells by Cluster	LTBP1 CDCA7 CDCA7L JAG1	3.93e-05	198	43	4	c724ef958e14e17a7d8c02b9f842510c0780f635
ToppCell	3'-Child04-06-SmallIntestine-Epithelial-epithelial_progenitor_cell\|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ERBB2 ERBB3 ZNRF3 CDCA7	3.93e-05	198	43	4	e8bfae3888b2406b5629b576cb02913b3297337e
ToppCell	Parenchymal-10x3prime_v2-Epithelial-Epi_airway_secretory\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	MET ERBB2 ERBB3 MUC5B	4.00e-05	199	43	4	a8bfc0b93ad9968cf52a25be86995ffe436bd636
ToppCell	Tracheal-NucSeq-Immune_Myeloid-Macrophage_alveolar\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	GRN TREML4 CSF3R P2RX7	4.00e-05	199	43	4	98c0d57c247d39bc771d81f4387f8dd01222628e
ToppCell	medial-2-mesenchymal-Myofibroblast\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	BRINP3 LTBP1 LTBP2 SCARF2	4.00e-05	199	43	4	95aae608fa35a9c82b12c6f18937ce636750ca44
ToppCell	tumor_Lung-Epithelial_cells-tS2\|tumor_Lung / Location, Cell class and cell subclass	MET ERBB2 ERBB3 TNFRSF21	4.00e-05	199	43	4	28ec59e01061287fb0892491790b316e2b93e232
ToppCell	Tracheal-NucSeq-Immune_Myeloid-Macrophage_alveolar-Macro_alveolar\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	GRN TREML4 CSF3R P2RX7	4.00e-05	199	43	4	b818d46a39c8782188d82dc8931b8eec9d549dd1
ToppCell	medial-mesenchymal-Myofibroblast\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	BRINP3 LTBP1 LTBP2 SCARF2	4.00e-05	199	43	4	e25acdb5809aaff631cb06dbe4c7e59549a0bdb9
ToppCell	medial-mesenchymal-Myofibroblast-2\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	BRINP3 LTBP1 LTBP2 SCARF2	4.00e-05	199	43	4	9ebf4822ff9fa08574edec5dbf4f2a1488f34b1d
ToppCell	Sigmoid-Macrophage-Macrophage\|Sigmoid / Region, Cell class and subclass	GRN CSF3R TNFRSF21 ITGB5	4.08e-05	200	43	4	9ee3a799de7bade1bfe94b6827461633f02bc1dc
ToppCell	Sigmoid-Macrophage\|Sigmoid / Region, Cell class and subclass	GRN CSF3R TNFRSF21 ITGB5	4.08e-05	200	43	4	b07ac0ff3b8530e99094678fed80f35949cafac8
ToppCell	Sigmoid-(6)_Macrophage-(60)_Macrophage\|Sigmoid / shred on region, Cell_type, and subtype	GRN CSF3R TNFRSF21 ITGB5	4.08e-05	200	43	4	ad84a83a5a1893f7b053d39eddeca851463a8ff0
ToppCell	Sigmoid-(6)_Macrophage\|Sigmoid / shred on region, Cell_type, and subtype	GRN CSF3R TNFRSF21 ITGB5	4.08e-05	200	43	4	9e10cca4429de2c4c8c3c6cf2c9e28637a095be9
ToppCell	Posterior_cortex-Macroglia-POLYDENDROCYTE-P1-P1_1-Trf-Oligodendrocyte.Tfr.Ctps_(Ctps)\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	ERBB3 SSPOP TSPAN10	9.01e-05	90	43	3	4d75217fd6b376bfda3300962cbe4875b31ffdaf
ToppCell	Endothelial-Endothelial-F\|Endothelial / shred on cell class and cell subclass (v4)	ERBB2 ZNFX1 GVINP1	2.22e-04	122	43	3	2cb8bb63c69aed4d4504b9d97219b8707666f950
ToppCell	Hippocampus-Macroglia-OLIGODENDROCYTE-O2-Trf\|Hippocampus / BrainAtlas - Mouse McCarroll V32	ERBB3 SSPOP TSPAN10	2.80e-04	132	43	3	dc6edfa821a1cdc645668b0af5ba5ff80dee10bd
ToppCell	Hippocampus-Macroglia-OLIGODENDROCYTE-O2\|Hippocampus / BrainAtlas - Mouse McCarroll V32	ERBB3 SSPOP TSPAN10	2.80e-04	132	43	3	60ced08bda5efc95a6f116cd0c6d1a779d99ed38
ToppCell	COVID-19_Moderate-B_cell\|World / disease group, cell group and cell class	ERBB3 LTBP2 GRM2	3.25e-04	139	43	3	b93e1da87d44e55d75e8cc1b87c2970645679c01
ToppCell	Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_granulocytic-neutrophil\|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	ILDR2 MUC5B CSF3R	3.99e-04	149	43	3	c5eedb54ef2e0f131aa6730612c921bc19479632
ToppCell	Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_granulocytic\|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	ILDR2 MUC5B CSF3R	3.99e-04	149	43	3	a22417286de8606f0cc94f86b70bce17aeefb9c2
ToppCell	droplet-Lung-3m-Hematologic-myeloid-intermediate_monocyte\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TREML4 CSF3R TNFRSF21	4.06e-04	150	43	3	b37f538ca5f976b509efe35dc81115b72b227084
ToppCell	droplet-Lung-3m-Hematologic-myeloid-intermediate_monocyte-intermediate_monocyte_l4\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TREML4 CSF3R TNFRSF21	4.06e-04	150	43	3	2c7518918c40e1bf679a2d4e83b472ee6f2f9df8
ToppCell	P15-Epithelial-epithelial_progenitor_cell\|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	ERBB3 MUC5B NALF2	4.23e-04	152	43	3	00d5503d462cfa009fb4cac79ecee11725a18b9a
ToppCell	facs-Brain_Myeloid-Cortex-3m-Myeloid-macrophage\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ERBB3 LTBP1 JAG1	4.31e-04	153	43	3	0ef7c45cdd854c79e527006034029767f8e108b2
ToppCell	5'-Adult-Appendix-Epithelial-Tuft-related-BEST4+_epithelial\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ILDR2 ERBB3 BRINP3	4.47e-04	155	43	3	5fabe24a784f0be46040ffc886eabd8d5ce78121
ToppCell	Children_(3_yrs)-Mesenchymal-airway_smooth_muscle_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ILDR2 BRINP3 LTBP1	4.47e-04	155	43	3	cd7d95cbcad248670e531d80bb83c55e36ebc573
ToppCell	Children_(3_yrs)-Epithelial-basal_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PRICKLE2 GOLGA8B MET	4.64e-04	157	43	3	6ee2692f705bdd93ba523dffaf2f0cd921b47e28
ToppCell	facs-Marrow-B-cells-24m-Myeloid-promonocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BRINP3 TREML4 TSPAN10	4.64e-04	157	43	3	0966e347f8d32b13f8a3b3afba3f64637c69cdf9
ToppCell	facs-Marrow-B-cells-24m-Myeloid-monocyte_+_promonocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BRINP3 TREML4 TSPAN10	4.64e-04	157	43	3	6ebfedd91d62c6d4aa8f046657a899a279f82ba2
ToppCell	TCGA-Bladder-Primary_Tumor-Urothelial_Carcinoma-Papillary_Muscle_Invasive_Urothelial_Carcinoma\|TCGA-Bladder / Sample_Type by Project: Shred V9	ERBB3 TNFRSF21 FER1L4	4.73e-04	158	43	3	dc559503bab3ec1b9ea54ef2e896d1be33e5344c
ToppCell	Club_cells-Donor_02\|World / lung cells shred on cell class, cell subclass, sample id	MET ERBB2 ERBB3	4.82e-04	159	43	3	a7bcff268b1962a561fd2848e01ae16565bce895
ToppCell	PND14-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-NK-NK_prolif\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	GVINP1 CDCA7 CDCA7L	4.82e-04	159	43	3	95128a2367ff2a639b21913c0350924c174faef8
ToppCell	droplet-Limb_Muscle-nan-24m-Myeloid-unknown\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CSF3R CDCA7 CDCA7L	4.82e-04	159	43	3	39033d49501a4ecc00af6c256e7a569c903ad332
ToppCell	TCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma-Stomach_Adenocarcinoma_-_Tubular-6\|TCGA-Stomach / Sample_Type by Project: Shred V9	MET WDR90 FER1L4	4.82e-04	159	43	3	655c0749c238bd68cb797adb83e25a23b8a3cc9d
ToppCell	facs-Lung-Endomucin-24m-Myeloid\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TREML4 CSF3R TSPAN10	4.82e-04	159	43	3	886cbaef39a3517514a3896b6b960d01a3af043d
ToppCell	3'-Child09-12-SmallIntestine-Epithelial-mature_enterocytic-Paneth\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	MUC5B ZNRF3 CDCA7	4.91e-04	160	43	3	6005948e400e781cdb876ba350b3ec8991e3945f
ToppCell	Children_(3_yrs)-Epithelial-lung_goblet_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	MET ERBB3 MUC5B	5.00e-04	161	43	3	2d63b279d9a5132e1c09b03930bf9039036d24a2
ToppCell	Posterior_cortex-Neuronal-Excitatory-eN1(Slc17a7)\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	MET GRM2 NALF2	5.00e-04	161	43	3	ba7ce599b173cf81c8323e7c96dc3d57379f1ed6
ToppCell	Myeloid\|World / shred on cell class and cell subclass (v4)	GRN CSF3R GVINP1	5.00e-04	161	43	3	aee407d3739dba2d5216dcdb1579e7e4f483123d
ToppCell	PND07-28-samps-Epithelial-Epithelial-non_alveolar-Club_cell\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	ERBB2 MUC5B FER1L4	5.09e-04	162	43	3	aed15eef32419b8a4e2afdb9776c2bf2802e96f1
ToppCell	343B-Myeloid-Dendritic-cDC_proliferating_2\|Dendritic / Donor, Lineage, Cell class and subclass (all cells)	ERBB2 LTBP2 ITGB5	5.27e-04	164	43	3	d7053de88ef8e42cac6726a40e72f212659ee034
ToppCell	Children_(3_yrs)-Mesenchymal-airway_smooth_muscle_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	BRINP3 LTBP1 LTBP2	5.27e-04	164	43	3	e3983f655cdba308fb192182829f17bef99ce0ba
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	LTBP1 CDCA7 JAG1	5.37e-04	165	43	3	4f83ac71efc57be3668d8db1e62bad05dc6a5e2b
ToppCell	facs-Lung-nan-3m-Myeloid\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TREML4 CSF3R TNFRSF21	5.37e-04	165	43	3	720649f330382ea2a68c64a5344160a048afb8f1
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	LTBP1 CDCA7 JAG1	5.37e-04	165	43	3	cd8de98af8a1a8a6c81d71fae807cc07f319f4c9
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PRICKLE2 MET ERBB3	5.46e-04	166	43	3	c20479fe7a4306320d7f26e78bf956225f00f35a
ToppCell	droplet-Lung-3m-Hematologic-myeloid\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TREML4 CSF3R TNFRSF21	5.56e-04	167	43	3	6f6f654d10cff83203415685f7707409626990ab
ToppCell	Adult-Mesenchymal-myofibroblast_cell\|Adult / Lineage, Cell type, age group and donor	LTBP1 LTBP2 ITGB5	5.56e-04	167	43	3	d584a8548a5317bd9686b3be8246ae6ed568796b
ToppCell	droplet-Lung-nan-18m-Myeloid\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CSF3R TNFRSF21 RGS19	5.66e-04	168	43	3	da1eee804456d910c17f145a5ce79c74a808a2c2
ToppCell	droplet-Marrow-BM-1m-Myeloid-basophil\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MET GVINP1 P2RX7	5.66e-04	168	43	3	2e88d9cb7c80a4656fab290db8b45a5a0599d769
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Myeloid-Dendritic\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	MET GRN TNFRSF21	5.75e-04	169	43	3	a0681317867e31319210a23e56660a53f4529efe
ToppCell	droplet-Spleen-nan-3m-Hematologic-proerythroblast\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TREML4 TNFRSF21 ITGB5	5.75e-04	169	43	3	91cfff1ad559cc327c6bb71c98aa29f0b3642568
ToppCell	facs-Liver-Non-hepatocytes-3m-Myeloid-Kupffer_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GRN TREML4 ITGB5	5.75e-04	169	43	3	44d841fd997a6f26104f16cd00223ecce8352f43
ToppCell	3'-Pediatric_IBD-SmallIntestine-Epithelial-Tuft-related-Microfold_cell\|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract	MET BRINP3 MUC5B	5.75e-04	169	43	3	a54a8494c1feff29d77ab4737fcfabc84ace5c94
ToppCell	facs-Liver-Non-hepatocytes-3m-Myeloid-nan\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GRN TREML4 ITGB5	5.75e-04	169	43	3	0f5e737b265ba333275a0cd289dab029a1542075
ToppCell	droplet-Spleen-nan-3m-Hematologic\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TREML4 TNFRSF21 ITGB5	5.75e-04	169	43	3	8e5e513090e86ca29fb61dfd388014774c506914
ToppCell	droplet-Thymus-nan-18m-Myeloid-Macrophage\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MET ERBB2 MEGF8	5.75e-04	169	43	3	4ac21e8199de4b6917eacadc56fffc6d886ee643
ToppCell	NS-critical-d_0-4-Epithelial-Secretory\|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	MET ERBB2 MUC5B	5.75e-04	169	43	3	aec97583b23112060437b619cb429dc32f29285f
ToppCell	facs-Liver-Non-hepatocytes-3m-Myeloid\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GRN TREML4 ITGB5	5.75e-04	169	43	3	aec1b4c7e973a31c53aaea47c2c05d24ce16aa4f
ToppCell	droplet-Spleen-nan-3m-Hematologic-nan\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TREML4 TNFRSF21 ITGB5	5.75e-04	169	43	3	972618e684321060c7af2429f853a6d639e8aae8
Computational	Placenta genes.	ERBB2 GRN ERBB3 LTBP1 LTBP2 CSF3R ITGB5 JAG1	3.66e-05	463	31	8	MODULE_38
Computational	Porins / transporters.	ERBB2 CSF3R P2RX7 TNFRSF21 ITGB5	3.12e-04	211	31	5	MODULE_63
Computational	Membranal receptors.	GRN GRM2 CSF3R P2RX7 TNFRSF21 ITGB5 JAG1	5.48e-04	517	31	7	MODULE_64
Drug	NVP-TAE684	MET ERBB2 ERBB3	2.81e-06	15	43	3	ctd:C516714
Drug	enzacamene	MET ERBB2 ERBB3 ITGB5 JAG1	4.37e-06	129	43	5	ctd:C038939
Drug	octylmethoxycinnamate	MET ERBB2 ERBB3 ITGB5 JAG1	6.30e-06	139	43	5	ctd:C118580
Drug	2-acetamidoethanethiol	ERBB2 ERBB3	1.04e-05	3	43	2	ctd:C023704
Drug	PHA665752	MET ERBB2 ERBB3	1.08e-05	23	43	3	CID010461815
Drug	benzylidenemalononitrile	ERBB2 GRN ERBB3	1.78e-05	27	43	3	CID000017608
Drug	Cbpg	GRM2 GRM4	2.09e-05	4	43	2	CID005311040
Drug	pM47	MT4 NALF2	2.09e-05	4	43	2	CID006334622
Drug	aurintricarboxylic acid	MT4 GRM2 GRM4 RGS19	2.62e-05	91	43	4	CID000002259
Drug	N-Acetyl-L-leucine [1188-21-2]; Down 200; 23uM; HL60; HT_HG-U133A	ATRN GBF1 CSF3R TNFRSF21 ITGB5	3.32e-05	196	43	5	3085_DN
Drug	Glimepiride [93479-97-1]; Down 200; 8.2uM; MCF7; HT_HG-U133A	ERBB2 GRN TNFRSF21 RGS19 JAG1	3.48e-05	198	43	5	2809_DN
Drug	AC1MBZ3L	GRM2 GRM4	5.20e-05	6	43	2	CID002733524
Drug	ZD-6	ERBB2 ERBB3	5.20e-05	6	43	2	CID010062753
Drug	cyclizine	OLIG3 ERBB3 GRM2 GRM4	6.77e-05	116	43	4	CID000006726
Drug	AC1L1JJ0	ERBB2 JAG1	7.27e-05	7	43	2	CID000005061
Drug	EGFR inhibitor	MET ERBB2 ERBB3 JAG1	7.73e-05	120	43	4	CID009549299
Drug	LSOs	GRN GRM2 GRM4 RSF1	8.78e-05	124	43	4	CID000164701
Drug	cis-MCG-I	GRM2 GRM4	9.69e-05	8	43	2	CID003035584
Drug	Folfox protocol	ERBB2 ERBB3	9.69e-05	8	43	2	ctd:C410216
Drug	AC1MPLNZ	ERBB2 MT4	9.69e-05	8	43	2	CID003387239
Drug	PKI166	MET ERBB2 ERBB3	1.02e-04	48	43	3	CID006918403
Drug	phorbol 12,13-diacetate	MT4 GRM2 GRM4	1.02e-04	48	43	3	CID000072293
Drug	AC1LD7MJ	MT4 GRM2 GRM4	1.09e-04	49	43	3	CID000643628
Drug	AC1N21PP	GRM2 GRM4	1.24e-04	9	43	2	CID004014619
Drug	AC1L18E1	MYF6 MYOG	1.24e-04	9	43	2	CID000000060
Drug	1,3-cyclopentanedicarboxylic acid	GRM2 GRM4	1.24e-04	9	43	2	CID000107216
Drug	mM PEP	GRM2 GRM4	1.24e-04	9	43	2	CID005311462
Drug	Su-M	ERBB2 GRN ERBB3	1.30e-04	52	43	3	CID000446388
Drug	sakyomicin A	MYF6 MT4 MYOG	1.46e-04	54	43	3	CID000124041
Drug	6-(methylamino)pyrido(3,4-d)pyrimidine	ERBB2 ERBB3	1.55e-04	10	43	2	ctd:C107875
Drug	NS-105	GRM2 GRM4	1.55e-04	10	43	2	CID000198695
Drug	2-[amino-[(2R,3R)-4-(benzylamino)-3-hydroxy-4-oxo-2-sulfanylbutanoyl]amino]acetic acid	MYF6 MYOG	1.90e-04	11	43	2	CID016122531
Drug	BE-23372M	ERBB2 ERBB3	1.90e-04	11	43	2	CID005311105
Drug	cyclobutylene AP5	GRM2 GRM4	1.90e-04	11	43	2	CID000126582
Drug	butylparaben	MET ERBB2 ERBB3 JAG1	2.18e-04	157	43	4	ctd:C038091
Drug	2-[amino-[(2R,3R)-4-benzoxy-3-hydroxy-4-keto-2-mercapto-butanoyl]amino]acetic acid	MYF6 MYOG	2.27e-04	12	43	2	CID016122530
Drug	pyridone	MT4 P2RX7	2.27e-04	12	43	2	CID000008871
Drug	homocysteic acid	GRN GRM2 GRM4	2.64e-04	66	43	3	CID000092117
Drug	AC1NSKBB	GRM2 GRM4	2.68e-04	13	43	2	CID005311256
Drug	CMF regimen	ERBB2 ERBB3	2.68e-04	13	43	2	ctd:C034456
Drug	Cpd1g-0	MYF6 MYOG	2.68e-04	13	43	2	CID000000577
Drug	Mspg	GRM2 GRM4	2.68e-04	13	43	2	CID003964410
Drug	MSOPPE	GRM2 GRM4	2.68e-04	13	43	2	CID005311463
Disease	Benign neoplasm of stomach	MET ERBB2 ERBB3	1.80e-06	17	42	3	C0153943
Disease	Neoplasm of uncertain or unknown behavior of stomach	MET ERBB2 ERBB3	1.80e-06	17	42	3	C0496905
Disease	Carcinoma in situ of stomach	MET ERBB2 ERBB3	1.80e-06	17	42	3	C0154060
Disease	Stomach Carcinoma	MET ERBB2 ERBB3	3.50e-06	21	42	3	C0699791
Disease	Epilepsy, Benign Psychomotor, Childhood	GRM2 GRM4 P2RX7	4.66e-06	23	42	3	C0393672
Disease	Epilepsy, Lateral Temporal	GRM2 GRM4 P2RX7	4.66e-06	23	42	3	C0393682
Disease	Uncinate Epilepsy	GRM2 GRM4 P2RX7	4.66e-06	23	42	3	C0014558
Disease	Epilepsy, Temporal Lobe	GRM2 GRM4 P2RX7	4.66e-06	23	42	3	C0014556
Disease	tongue squamous cell carcinoma (is_marker_for)	MET ERBB3 BRINP3	2.01e-05	37	42	3	DOID:0050865 (is_marker_for)
Disease	Head and Neck Carcinoma	ERBB2 ERBB3	8.84e-05	10	42	2	C3887461
Disease	gallbladder neoplasm	ERBB2 ERBB3	1.08e-04	11	42	2	C0016978
Disease	Malignant neoplasm of gallbladder	ERBB2 ERBB3	1.08e-04	11	42	2	C0153452
Disease	pulse pressure measurement	MET LTBP1 LTBP2 MEGF8 GRM4 CDCA7 SSPOP ITGB5 JAG1	1.23e-04	1392	42	9	EFO_0005763
Disease	median neuropathy (biomarker_via_orthology)	ERBB2 ERBB3	1.78e-04	14	42	2	DOID:571 (biomarker_via_orthology)
Disease	dilated cardiomyopathy (implicated_via_orthology)	ERBB2 LTBP2 JAG1	2.04e-04	80	42	3	DOID:12930 (implicated_via_orthology)
Disease	Nerve Degeneration	ATRN GRN GRM4	2.28e-04	83	42	3	C0027746
Disease	laryngeal squamous cell carcinoma (is_marker_for)	ERBB2 ERBB3	3.33e-04	19	42	2	DOID:2876 (is_marker_for)
Disease	Adenocarcinoma of large intestine	MET ERBB2 ZNRF3	3.49e-04	96	42	3	C1319315
Disease	anti-Mullerian hormone measurement	ZNRF3 CDCA7	3.70e-04	20	42	2	EFO_0004769
Disease	Nasopharyngeal carcinoma	ERBB2 ERBB3	4.49e-04	22	42	2	C2931822
Disease	Neoplasm of the genitourinary tract	MET ERBB2	5.35e-04	24	42	2	cv:C0042065
Disease	stomach carcinoma (is_marker_for)	ERBB2 ERBB3	5.35e-04	24	42	2	DOID:5517 (is_marker_for)
Disease	Lung Neoplasms	MET ERBB2 ERBB3 JAG1	5.44e-04	265	42	4	C0024121
Disease	Malignant neoplasm of lung	MET ERBB2 ERBB3 JAG1	5.52e-04	266	42	4	C0242379
Disease	migraine disorder, diastolic blood pressure	KIAA0040 ITGB5	5.81e-04	25	42	2	EFO_0006336, MONDO_0005277
Disease	Lymphatic Metastasis	MET ERBB2	6.29e-04	26	42	2	C0024232
Disease	cerebral white matter volume change measurement, age at assessment	PRICKLE2 TNFRSF21	7.30e-04	28	42	2	EFO_0008007, EFO_0021499
Disease	intraocular pressure measurement	LTBP1 LTBP2 ZNRF3 NALF2 TSPAN10	7.53e-04	509	42	5	EFO_0004695
Disease	Malignant Neoplasms	MET ERBB2 ERBB3	8.09e-04	128	42	3	C0006826
Disease	intestinal cancer (implicated_via_orthology)	ERBB2 ERBB3	9.55e-04	32	42	2	DOID:10155 (implicated_via_orthology)
Disease	Head and Neck Neoplasms	ERBB2 ERBB3	1.02e-03	33	42	2	C0018671
Disease	Duchenne muscular dystrophy (implicated_via_orthology)	MYF6 MYOG	1.21e-03	36	42	2	DOID:11723 (implicated_via_orthology)
Disease	ductal carcinoma in situ (is_marker_for)	ERBB2 ERBB3	1.42e-03	39	42	2	DOID:0060074 (is_marker_for)

Protein segments in the cluster

Peptide	Gene	Start	Entry
ACHPCSPMCKGSRCW	ERBB2	191	P04626
RSCPPCHEVCKGRCW	ERBB3	181	P21860
NDCWCHCGPKFPECN	BRINP3	276	Q76B58
PWLQPCCGHFPFCSC	ARSD	571	P51689
SVQPGEVCCWLCIPC	GRM2	511	Q14416
KTVKGMPCCWHCEPC	GRM4	531	Q14833
HLCGCWKQCPSCGAI	GVINP1	2281	Q7Z2Y8
WGCCPIPEAVCCSDH	GRN	386	P28799
GGSWACCQLPHAVCC	GRN	461	P28799
WHYQPCGAPCLKTCR	MUC5B	1166	Q9HC84
CTCSHCLEQPGCGWC	ATRN	991	O75882
ITLLFICCHCCWSPP	KIAA0040	41	Q15053
ICCHCCWSPPGKRGQ	KIAA0040	46	Q15053
CLPLCHCKPCMHVWS	FER1L4	516	A9Z1Z3
LCCCSVGKAWGPHCE	LTBP1	701	Q14766
PHCPGQCLIWACKTC	MYF6	71	P23409
TPRCKWCTNCPEGAC	MEGF8	1951	Q7Z7M0
CCCCWAPRPSDKPCA	NALF2	21	O75949
WVCPPCRGICNCSYC	CDCA7L	401	Q96GN5
CEECLLIHPKCAWCS	ITGB5	36	P18084
NCKTYWKSCCPCCPP	MT4	26	P47944
FQHWAGLPCPCTICQ	OLIG3	231	Q7RTU3
HGVCWHPPCFVCTVC	PRICKLE2	151	Q7Z3G6
HIYPWCKCCQPCVVN	P2RX7	366	Q99572
CLCGTAWLCCSPNRK	CSF3R	641	Q99062
CWCPANSTGKFCHLP	LTBP2	416	Q14767
CWCPLLQGIACLCCD	GBF1	1541	Q92538
HPGLGSNCCVPCFCW	GOLGA8B	581	A8MQT2
GEWFCPPCQHKLLCE	RSF1	931	Q96T23
CVHGICNEPWQCLCE	JAG1	271	P78504
ACSKVWCGPRPCLLH	JAG1	891	P78504
SAPPFVQCGWCHDKC	MET	531	P08581
PAAPSRNPCCLCWCC	RGS19	31	P49795
WILPHGTCPICKCDI	RNF133	286	Q8WVZ7
CDDLVHCVWRCQPGC	SSPOP	3331	A2VEC9
ATSCPCLCWHLQPGA	SSPOP	4831	A2VEC9
NGIEKCHDCSQPCPW	TNFRSF21	101	O75509
PNWHCPPCRGICNCS	CDCA7	316	Q9BWT1
WLACCCCLSLPGQLP	C11orf21	86	Q9P2W6
LNQSCLCLAWSPPCC	WDR90	1476	Q96KV7
FHLCCCCSWPQGAVP	TREML4	11	Q6UXN2
FVLVGICWCQCCPHS	ILDR2	201	Q71H61
QFWGPDCKELCSCHP	SCARF2	116	Q96GP6
LCSPCVEPCVWRCQH	ZNFX1	1506	Q9P2E3
EAWGCSCCPPETKHQ	TSPAN10	41	Q9H1Z9
WKGGHELPSCACCCE	ZNRF3	701	Q9ULT6
QCPHHCPVLGCWSGC	PRO3102	61	Q9H379
CPGQCLPWACKVCKR	MYOG	61	P15173